Second dose of the BNT162b2 mRNA vaccine: Value of timely administration but questionable necessity among the seropositive

This study monitored titers of neutralizing IgG against the receptor-binding domain of the SARS-CoV-2 S1 subunit 14 days post-injection of each dose of the BNT162b2 mRNA Covid-19 vaccine in 401 Greek healthcare workers aged 20–67. After the first dose, titers varied upon age and history of infection...

Descripción completa

Detalles Bibliográficos
Autores principales: Kontopoulou, Konstantina, Ainatzoglou, Alexandra, Nakas, Christos T., Ifantidou, Athina, Goudi, Georgia, Antoniadou, Eleni, Adamopoulos, Vasilios, Papadopoulos, Nikitas, Papazisis, Georgios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325516/
https://www.ncbi.nlm.nih.gov/pubmed/34344551
http://dx.doi.org/10.1016/j.vaccine.2021.07.065
Descripción
Sumario:This study monitored titers of neutralizing IgG against the receptor-binding domain of the SARS-CoV-2 S1 subunit 14 days post-injection of each dose of the BNT162b2 mRNA Covid-19 vaccine in 401 Greek healthcare workers aged 20–67. After the first dose, titers varied upon age and history of infection, being lower in the 50+ age group and significantly higher among the seropositive. After the second dose, immunogenicity was significantly boosted in the age 50+ and SARS-CoV-2-naïve individuals, indicating the effectuality of its timely administration, yet questioning its value among the seropositive.

Ejemplares similares